Please click for Full Prescribing Information for TAKHZYRO.
Please click for Full Prescribing Information for TAKHZYRO.

Welcome to Support and Resources

Access more information about TAKHZYRO, On-Demand Treatment, and OnePath® Product Support.

Choose a category:

TAKHZYRO Brochures

Clinical Studies Brochure

Learn more about the clinical studies of TAKHZYRO, including the open-label study.

Case Study Brochure (Jason)

Explore the patient journey of Jason, a real TAKHZYRO patient. See why Dr Johnston thought TAKHZYRO was appropriate for Jason.

Case Study Brochure (Lisa)

Explore the patient journey of Lisa, a real TAKHZYRO patient. See why Dr Bowser thought TAKHZYRO was appropriate for Lisa.

On-Demand Treatment Brochures

On-Demand Treatment Brochure for Healthcare Providers

Learn about the role of an on-demand treatment option in a patient’s management plan.

*TAKHZYRO is not an on-demand treatment.

On-Demand Treatment Brochure for Patients

Help patients understand how an on-demand treatment option could be a part of their management plan.

*TAKHZYRO is not an on-demand treatment.

OnePath Product Support

OnePath Product Support

OnePath Brochure for Healthcare Providers

Learn how OnePath can provide product support for your patients prescribed a Takeda medication.

INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Scroll to Top

For US Healthcare Professionals Only

The information on this website has been specifically created for US healthcare professionals (HCPs).

You are now leaving the Homepage and entering the Medical Affairs Area.

Yes, I want to leave